{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:12:49Z","timestamp":1792699969487,"version":"4.5.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>\n                    Sodium glucose cotransporter\u20102 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was conducted in patients with type 2 diabetes with NAFLD. The changes in glycemic control, obesity, and liver pathology were compared between participants taking ipragliflozin (50\u00a0mg\/day for 72\u00a0weeks; IPR group) and participants being managed without SGLT2is, pioglitazone, glucagon\u2010like peptide\u20101 analogs, or insulin (CTR group). In the IPR group (n\u00a0=\u00a025), there were significant decreases in hemoglobin A1c (HbA1c) and body mass index (BMI) during the study (HbA1c, \u22120.41%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u00a0&lt;\u00a00.01; BMI, \u22121.06\u00a0kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u00a0&lt;\u00a00.01), whereas these did not change in the CTR group (n\u00a0=\u00a026). Liver pathology was evaluated in 21\/25 participants in the IPR\/CTR groups, and hepatic fibrosis was found in 17 (81%) and 18 (72%) participants in the IPR and CTR groups at baseline. This was ameliorated in 70.6% (12 of 17) of participants in the IPR group and 22.2 % (4 of 18) of those in the CTR group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u00a0&lt;\u00a00.01). Nonalcoholic steatohepatitis (NASH) resolved in 66.7% of IPR\u2010treated participants and 27.3% of CTR participants. None of the participants in the IPR group developed NASH, whereas 33.3% of the CTR group developed NASH.\n                    <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>\n                    : Long\u2010term ipragliflozin treatment ameliorates hepatic fibrosis in patients with NAFLD. Thus, ipragliflozin might be effective for the treatment and prevention of NASH in patients with diabetes, as well as improving glycemic control and obesity. Therefore, SGLT2is may represent a therapeutic choice for patients with diabetes with NAFLD, but further larger studies are required to confirm these effects.\n                  <\/jats:p>","DOI":"10.1002\/hep4.1696","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T04:46:55Z","timestamp":1623905215000},"page":"120-132","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":152,"title":["Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-2889","authenticated-orcid":false,"given":"Hirokazu","family":"Takahashi","sequence":"first","affiliation":[{"name":"Division of Metabolism and Endocrinology,Faculty of Medicine,Saga University,Saga,Japan"},{"name":"Liver Center, Saga University Hospital,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Graduate School of Medicine,Yokohama City University,Yokohama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Kawanaka","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine Kawasaki Medical Center,Kawasaki Medical School,Okayama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,JA Hiroshima General Hospital,Hatsukaichi,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hyogo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,JA Hiroshima General Hospital,Hatsukaichi,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-9623","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Osaka City Juso Hospital,Osaka,Japan"},{"name":"Department of Premier Preventive Medicine,Osaka City University Graduate School of Medicine,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hepatology,Sapporo Kosei General Hospital,Sapporo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Graduate School of Medicine,Yokohama City University,Yokohama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oeda","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kurai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Osaka City Juso Hospital,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Graduate School of Medicine,Yokohama City University,Yokohama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[{"name":"Internal Medicine,Tokyo Women\u2019s Medical University Medical Center East,Tokyo,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology,Faculty of Medicine,Saga University,Saga,Japan"},{"name":"Department of Clinical Gastroenterology,Eguchi Hospital,Ogi,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Clinical Research Center,Saga University Hospital,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takamori","sequence":"additional","affiliation":[{"name":"Clinical Research Center,Saga University Hospital,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Education and Research Center for Community Medicine,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Aishima","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Kage","sequence":"additional","affiliation":[{"name":"Kurume University Research Center for Innovative Cancer Therapy,Kurume,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Graduate School of Medicine,Yokohama City University,Yokohama,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology,Faculty of Medicine,Saga University,Saga,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"hep41696-bib-0001-20241114","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on non\u2010alcoholic fatty liver disease and non\u2010alcoholic steatohepatitis","volume":"69","year":"2019","journal-title":"Hepatology"},{"key":"hep41696-bib-0002-20241114","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","year":"2016","journal-title":"Hepatology"},{"key":"hep41696-bib-0003-20241114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","year":"2018","journal-title":"Hepatology"},{"key":"hep41696-bib-0004-20241114","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2008.01.016","article-title":"Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with nonalcoholic fatty liver disease","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep41696-bib-0005-20241114","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta\u2010analysis","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"hep41696-bib-0006-20241114","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"hep41696-bib-0007-20241114","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep41696-bib-0008-20241114","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","year":"2007","journal-title":"Hepatology"},{"key":"hep41696-bib-0009-20241114","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta\u2010analysis","volume":"65","year":"2017","journal-title":"Hepatology"},{"key":"hep41696-bib-0010-20241114","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"hep41696-bib-0011-20241114","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"hep41696-bib-0012-20241114","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","year":"2018","journal-title":"Circulation"},{"key":"hep41696-bib-0013-20241114","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","year":"2020","journal-title":"Diabetologia"},{"key":"hep41696-bib-0014-20241114","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","year":"2020","journal-title":"Dig Dis Sci"},{"key":"hep41696-bib-0015-20241114","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/hepr.13304","article-title":"Impact of SGLT2 inhibitor to histological features and glucose metabolism of non\u2010alcoholic fatty liver disease complicated by diabetes mellitus","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41696-bib-0016-20241114","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"hep41696-bib-0017-20241114","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2337\/diacare.19.10.1138","article-title":"A prospective analysis of the HOMA model. The Mexico City Diabetes Study","volume":"19","year":"1996","journal-title":"Diabetes Care"},{"key":"hep41696-bib-0018-20241114","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0168-8278(96)80023-7","article-title":"Comparison of serum 7S fragment of type IV collagen and serum central triple\u2010helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease","volume":"24","year":"1996","journal-title":"J Hepatol"},{"key":"hep41696-bib-0019-20241114","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00535-014-0946-y","article-title":"A novel serum marker, glycosylated Wisteria floribunda agglutinin\u2010positive Mac\u20102 binding protein (WFA(+)\u2010M2BP), for assessing liver fibrosis","volume":"50","year":"2015","journal-title":"J Gastroenterol"},{"key":"hep41696-bib-0020-20241114","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1148\/radiology.211.1.r99ap15283","article-title":"Abdominal fat: standardized technique for measurement at CT","volume":"211","year":"1999","journal-title":"Radiology"},{"key":"hep41696-bib-0021-20241114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","year":"2005","journal-title":"Hepatology"},{"key":"hep41696-bib-0022-20241114","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"hep41696-bib-0023-20241114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","year":"1999","journal-title":"Gastroenterology"},{"key":"hep41696-bib-0024-20241114","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/14656566.2016.1217994","article-title":"Baseline characteristics and interim (3\u2010month) efficacy and safety data from STELLA\u2010LONG TERM, a long\u2010term post\u2010marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real\u2010world clinical practice","volume":"17","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"hep41696-bib-0025-20241114","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/dia.2011.0012","article-title":"Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium\u2010dependent glucose co\u2010transporter 2, in patients with type 2 diabetes mellitus","volume":"13","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"hep41696-bib-0026-20241114","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/dom.12331","article-title":"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double\u2010blind, placebo\u2010controlled study","volume":"17","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"hep41696-bib-0027-20241114","doi-asserted-by":"crossref","first-page":"222","DOI":"10.18433\/jpps29831","article-title":"Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: a meta\u2010analysis of randomized controlled trials","volume":"21","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"hep41696-bib-0028-20241114","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA\u2010REG OUTCOME\u00ae trial","volume":"61","year":"2018","journal-title":"Diabetologia"},{"key":"hep41696-bib-0029-20241114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13300-017-0355-3","article-title":"Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single\u2010center, retrospective","volume":"9","year":"2018","journal-title":"Observ Study Diabetes Ther"},{"key":"hep41696-bib-0030-20241114","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.diabres.2018.05.017","article-title":"Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus","volume":"142","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"hep41696-bib-0031-20241114","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non\u2010alcoholic fatty liver disease: a prospective randomized controlled pilot study","volume":"20","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"hep41696-bib-0032-20241114","first-page":"812","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"hep41696-bib-0033-20241114","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.biopha.2018.06.062","article-title":"Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite\u2010regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats","volume":"105","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"hep41696-bib-0034-20241114","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"hep41696-bib-0035-20241114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non\u2010alcoholic fatty liver disease: a prospective, single\u2010arm trial (LEAD trial)","volume":"49","year":"2019","journal-title":"Hepatol Res"},{"key":"hep41696-bib-0036-20241114","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep41696-bib-0037-20241114","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"hep41696-bib-0038-20241114","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","year":"2015","journal-title":"Nat Med"},{"key":"hep41696-bib-0039-20241114","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI115997","article-title":"Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study","volume":"90","year":"1992","journal-title":"J Clin Invest"},{"key":"hep41696-bib-0040-20241114","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1\u2010mediated hepatic lipolysis","volume":"579","year":"2020","journal-title":"Nature"},{"key":"hep41696-bib-0041-20241114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2017.09.081","article-title":"Effect of sodium\u2010glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver\u2010brain\u2010adipose neurocircuitry","volume":"493","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"hep41696-bib-0042-20241114","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1139\/cjpp-2017-0683","article-title":"Coagonist of glucagon\u2010like peptide\u20101 and glucagon receptors ameliorates nonalcoholic fatty liver disease","volume":"96","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"hep41696-bib-0043-20241114","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future perspectives on GLP\u20101 receptor agonists and GLP\u20101\/glucagon receptor co\u2010agonists in the treatment of NAFLD","volume":"9","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"hep41696-bib-0044-20241114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.semdp.2006.11.002","article-title":"Alcoholic liver disease","volume":"23","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"hep41696-bib-0045-20241114","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2008.01.026","article-title":"Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep41696-bib-0046-20241114","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/dmrr.2407","article-title":"Sodium\u2010glucose cotransporter 2\u2010mediated oxidative stress augments advanced glycation end products\u2010induced tubular cell apoptosis","volume":"29","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"hep41696-bib-0047-20241114","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/ijms21010190","article-title":"Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules","volume":"21","year":"2019","journal-title":"Int J Mol Sci"},{"key":"hep41696-bib-0048-20241114","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/s41598-019-51343-1","article-title":"Hypoxia\u2010inducible factor\u20101\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy","volume":"9","year":"2019","journal-title":"Sci Rep"},{"key":"hep41696-bib-0049-20241114","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep.24038","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease","volume":"53","year":"2011","journal-title":"Hepatology"},{"key":"hep41696-bib-0050-20241114","doi-asserted-by":"crossref","first-page":"G117","DOI":"10.1152\/ajpgi.00246.2015","article-title":"Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice","volume":"310","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:02:10Z","timestamp":1731564130000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1696","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"2020-10-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}